Corrigendum to “Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study” [eClinicalMedicine 73(2024) 102655]
dc.contributor.author | Passeron, Thierry | |
dc.contributor.author | Ezzedine, Khaled | |
dc.contributor.author | Hamzavi, lltefat | |
dc.contributor.author | van Geel, Nanja | |
dc.contributor.author | Schlosser, Bethanee J. | |
dc.contributor.author | Wu, Xiaoqiang | |
dc.contributor.author | Huang, Xiaohong | |
dc.contributor.author | Soliman, Ahmed M. | |
dc.contributor.author | Rosmarin, David | |
dc.contributor.author | Harris, John E. | |
dc.contributor.author | Camp, Heidi S. | |
dc.contributor.author | Pandya, Amit G. | |
dc.contributor.department | Dermatology, School of Medicine | |
dc.date.accessioned | 2025-05-20T10:38:54Z | |
dc.date.available | 2025-05-20T10:38:54Z | |
dc.date.issued | 2025-03-19 | |
dc.description.abstract | [This corrects the article DOI: 10.1016/j.eclinm.2024.102655.]. | |
dc.eprint.version | Final published version | |
dc.identifier.citation | Passeron T, Ezzedine K, Hamzavi L, et al. Corrigendum to "Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study" [eClinicalMedicine 73(2024) 102655]. EClinicalMedicine. 2025;82:103167. Published 2025 Mar 19. doi:10.1016/j.eclinm.2025.103167 | |
dc.identifier.uri | https://hdl.handle.net/1805/48259 | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | |
dc.relation.isversionof | 10.1016/j.eclinm.2025.103167 | |
dc.relation.journal | eClinicalMedicine | |
dc.rights | Publisher Policy | |
dc.source | PMC | |
dc.subject | Clinical trial | |
dc.subject | Phase 3 | |
dc.subject | Janus kinase inhibitors | |
dc.subject | Randomised controlled trial | |
dc.subject | Upadacitinib | |
dc.subject | Vitiligo | |
dc.title | Corrigendum to “Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study” [eClinicalMedicine 73(2024) 102655] | |
dc.type | Article | |
ul.alternative.fulltext | https://pmc.ncbi.nlm.nih.gov/articles/PMC11968280/ |